Recombinant Human Anti-FGF2 x Human Anti-VEGF Bispecific Antibody (scIgG) (SCIGG-H326)

Recombinant Anti-FGF2 x Anti-VEGF Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-FGF2 and anti-VEGF IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two ligands simultaneously. It is designed for the research of Hepatocellular cancer (HCC); Breast cancer; Colon cancer; Lung cancer; Glioma cancer therapy.

Datasheet INQUIRY

Specifications

Targets

FGF2 & VEGF

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Hepatocellular cancer (HCC); Breast cancer; Colon cancer; Lung cancer; Glioma cancer

Targets

Target 1

FGF2

Gene ID

2247

UniProt ID

P09038

Alternative Names

FGF; Fibroblast growth factor; FGF2; fibroblast growth factor 2; BFGF; FGFB; FGF-2; HBGF-2

Target 2

VEGF

Gene ID

7422

UniProt ID

P15692

Alternative Names

VEGFA; vascular endothelial growth factor A; VPF; VEGF; MVCD1; vascular permeability factor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-FGF2 x Human Anti-VEGF Bispecific Antibody (scIgG) (SCIGG-H326). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-FGF2 x Human Anti-VEGF Bispecific Antibody (scIgG) (CAT#: SCIGG-H326)

Specifications

Targets

Customer Reviews and Q&As